Relmada Therapeutics, Inc. Common Stock (RLMD) Stock Price

RLMDStock
$4.59+630.46%52W
Market Cap$489.61M
P/E
PEG Ratio
Div yield
Beta0.50

RLMD Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)1.01%
Price vs S&P 500 (4W)-15.48%
VGM Score51.04

RLMD Earnings Surprise History

Q3 25-0.30est.
Q4 25-0.29est. -0.14
Q2 26-0.11est. -0.20

RLMD Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.27
4.27
4.25
4.25

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
RLMDRelmada Therapeutics, Inc. Common Stock
C$4.59
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Relmada Therapeutics, Inc. Common Stock

Relmada Therapeutics is a clinical-stage biotech company developing esmethadone (REL-1017), an oral NMDA receptor antagonist for depression and other central nervous system disorders. The company is focused on addressing high unmet medical needs in CNS disease treatment through novel drug formulations.